Ladenburg Thalmann Financial Services initiated coverage on shares of InVitae (NYSE:NVTA) in a report issued on Friday, MarketBeat reports. The brokerage issued a buy rating and a $15.00 price objective on the medical research company’s stock.
NVTA has been the topic of a number of other research reports. BidaskClub cut shares of InVitae from a buy rating to a hold rating in a research report on Thursday, October 26th. Zacks Investment Research cut shares of InVitae from a hold rating to a sell rating in a research report on Thursday, January 4th. Finally, Leerink Swann reduced their price target on shares of InVitae from $14.00 to $12.00 and set an outperform rating on the stock in a research report on Tuesday, November 7th. Three analysts have rated the stock with a sell rating and four have issued a buy rating to the company. InVitae presently has an average rating of Hold and an average target price of $13.80.
InVitae (NYSE NVTA) traded down $1.42 during mid-day trading on Friday, hitting $8.63. 2,005,900 shares of the company’s stock were exchanged, compared to its average volume of 833,520. InVitae has a 12-month low of $2.70 and a 12-month high of $10.41. The stock has a market capitalization of $465.92 and a PE ratio of -3.38. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.61 and a quick ratio of 2.61.
ILLEGAL ACTIVITY WARNING: “InVitae (NVTA) Coverage Initiated by Analysts at Ladenburg Thalmann Financial Services” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.com-unik.info/2018/01/09/invitae-nvta-coverage-initiated-by-analysts-at-ladenburg-thalmann-financial-services.html.
InVitae Company Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.